Apremilast for immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis: A systematic review
Published: 29 November 2024| Version 1 | DOI: 10.17632/22frj4rmbz.1
Contributors:
Manjit kaur, Anna-Elise Feldman, Brittany Dulmage, Jessica Kaffenberger, Benjamin KaffenbergerDescription
We conducted a systematic review of Apremilast for treating immune checkpoint inhibitor-associated psoriasis and psoriatic arthritis. Supplementary File 1. Search Strategy and Eligibility Criteria. Supplementary File 2. Complete List of References. Supplementary Table I. List of Included Studies, Characteristics of Psoriasis/Psoriasiform Eruption and Outcome after Apremilast Use. Supplementary Table II & III. Risk of Bias Assessment of Included Studies.
Files
Categories
Psoriatic Arthritis, Systematic Review, Psoriasis